Bunnell Incorporated

Bunnell Incorporated is a United States medical-equipment company established in 1980 with support from the University of Utah's Innovation Center, a project funded by the National Science Foundation. The company is chiefly associated with the Life Pulse Ventilator, a high-frequency ventilator developed for clinical respiratory care and particularly significant in neonatal medicine. The device became the company's first and most prominent product and was the first high-frequency ventilator approved by the U.S. Food and Drug Administration for clinical use, receiving approval on June 30, 1988. Bunnell's development history illustrates the difficulty of bringing a specialized medical device from research into regulated clinical practice. In 1982, the company began clinical trials of the Life Pulse Ventilator at five medical centers located in Utah, Arizona, Minnesota, Pennsylvania, and Florida. These trials created a multi-state clinical base for evaluating the device in hospital settings. By 1985, the ventilator had been used to treat almost 100 infants, providing clinical experience for the company's regulatory submission. Bunnell then submitted a substantial application to the FDA: twelve copies of an application described as nearly one thousand pages. The initial submission was rejected, and the application continued to face rejection over the following three years. During this period, the company accumulated approximately $2 million in debt, placing significant financial pressure on the business while it continued pursuing regulatory clearance. The FDA ultimately granted approval on June 30, 1988. The Life Pulse Ventilator's approval was the central turning point in Bunnell's documented history. It established the company as a medical-device developer with a product capable of meeting U.S. clinical and regulatory requirements, while also marking an important milestone for high-frequency ventilation in clinical care. Publicly available reference material identifies Bunnell primarily through this product and its regulatory history. It does not provide enough information to confirm the company's present ownership, headquarters, broader product portfolio, current leadership, financial condition, or continued operating status. Those fields therefore remain unspecified rather than inferred.

Bunnell Incorporated was founded in 1980 as a medical-equipment company supported by the University of Utah's Innovation Center. The innovation center was a project funded by the National Science Foundation, linking Bunnell's early development work to an academic and federally supported innovation environment. The available historical account does not identify a specific individual founder, instead emphasizing the institutional assistance that helped the company begin its work. The company's principal documented project was the Life Pulse Ventilator, a high-frequency ventilator intended for clinical respiratory care. In 1982, Bunnell began clinical trials at five medical centers in Utah, Arizona, Minnesota, Pennsylvania, and Florida. The geographic spread of these sites gave the company experience across multiple hospital settings and provided clinical evidence for its later regulatory application. By 1985, almost 100 infants had been treated with the device. Bunnell's attempt to secure FDA approval became a lengthy and financially difficult stage in the company's development. It submitted twelve copies of an application described as nearly one thousand pages. The FDA rejected the application, and the company continued to encounter rejection for three years. During this regulatory process, Bunnell accumulated approximately $2 million in debt. The available account presents the debt as a consequence of the prolonged approval effort, but it does not provide additional information about financing arrangements, investors, revenue, or eventual repayment. On June 30, 1988, the FDA granted approval for the Life Pulse Ventilator. The approval was historically important for Bunnell because the device was identified as the first high-frequency ventilator approved by the FDA for clinical use. It also represented the culmination of the company's clinical trials, regulatory submissions, and sustained development effort. The product's association with infant treatment and high-frequency ventilation forms the central basis of Bunnell's documented identity as a medical-device company. The available reference material contains little information about Bunnell after the 1988 approval. It does not establish a current headquarters, ownership structure, executive roster, website, public listing, later products, acquisitions, or present operating status. Accordingly, the company's later corporate history and current market position require further verification.

• 1988

  Life Pulse Ventilator receives FDA approval

  [1]Bunnell Incorporateden.wikipedia.org

  On June 30, 1988, the FDA approved the Life Pulse Ventilator for clinical use, making it the first high-frequency ventilator identified in the reference account as receiving such approval.

• 1985

  Clinical experience expands and FDA submission is made

  [1]Bunnell Incorporateden.wikipedia.org

  The Life Pulse Ventilator had treated almost 100 infants, after which Bunnell submitted a large application to the FDA for approval.

• 1982

  Life Pulse Ventilator clinical trials begin

  [1]Bunnell Incorporateden.wikipedia.org

  Clinical trials began at five medical centers in Utah, Arizona, Minnesota, Pennsylvania, and Florida.

• 1980

  Company established with University of Utah support

  [1]Bunnell Incorporateden.wikipedia.org

  Bunnell Incorporated was established with help from the University of Utah's Innovation Center, an initiative funded by the National Science Foundation.

Specialized medical-device developer focused on high-frequency ventilation and clinical respiratory care, with a documented emphasis on infant and neonatal treatment.

• High-frequency clinical ventilator · 1988

  Life Pulse Ventilator

  The Life Pulse Ventilator was Bunnell Incorporated's first and best-known product. It was a high-frequency ventilator developed for clinical respiratory care and used in trials involving infants. Clinical testing began in 1982 at five medical centers, and the device had treated almost 100 infants by 1985. Following a prolonged FDA review process, the ventilator received U.S. approval for clinical use on June 30, 1988. The available source identifies it as the first high-frequency ventilator approved by the FDA for clinical use.

• 1988

  Pursuit of FDA approval for the Life Pulse VentilatorProduct launch

  Background

  Bunnell pursued U.S. regulatory clearance after clinical trials at five medical centers and treatment of almost 100 infants. Its initial application was rejected, and the approval effort continued for three years while the company reportedly accumulated approximately $2 million in debt.

  Action taken

  The company continued its regulatory effort and obtained FDA approval for the Life Pulse Ventilator on June 30, 1988.

  Aftermath

  The approval established the Life Pulse Ventilator as the first high-frequency ventilator approved by the FDA for clinical use, according to the reference account.

  Reported debt during the approval process. $2 million debt (By the three-year FDA review period ending in 1988)

  Source

• 1988

  FDA approves Bunnell's Life Pulse Ventilator[1]Bunnell Incorporateden.wikipedia.org

  Product launch · Regulation

  The U.S. Food and Drug Administration granted approval on June 30, 1988, for Bunnell's Life Pulse Ventilator. The device was described as the first high-frequency ventilator approved by the FDA for clinical use.

• 1985

  Bunnell submits extensive FDA application after infant clinical use[1]Bunnell Incorporateden.wikipedia.org

  Regulation · Product launch

  After the Life Pulse Ventilator had been used to treat almost 100 infants, Bunnell submitted a large FDA application seeking approval. The application was subsequently rejected and revised over a period of several years.

1. 1Bunnell Incorporateden.wikipedia.org